New clinical responses for agen1181 presented at aacr

Lexington, mass., april 10, 2021 (globe newswire) -- agenus (nasdaq: agen), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today presented new clinical data on agen1181, its next-generation anti-ctla-4 antibody, at the american association for cancer research (aacr) annual meeting from april 10 - 15, 2021.
AGEN Ratings Summary
AGEN Quant Ranking